Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)

• Yutaka Fujiwara ,

  * E-mail: yutakafu@ncc.go.jp

  Affiliations Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan, Department of Experimental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital, Tokyo, Japan

  ⨯
• Shogo Kobayashi,

  Affiliation Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan

  ⨯
• Hiroaki Nagano,

  Affiliation Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan

  ⨯
• Masashi Kanai,

  Affiliation Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan

  ⨯
• Etsuo Hatano,

  Affiliation Department of Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan

  ⨯
• Masanori Toyoda,

  Affiliation Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Tetsuo Ajiki,

  Affiliation Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Yuki Takashima,

  Affiliation Department of Clinical Pharmacology, Fundamental Innovative Oncology Core, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Kenichi Yoshimura,

  Affiliation Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan

  ⨯
• Akinobu Hamada,

  Affiliation Department of Clinical Pharmacology, Fundamental Innovative Oncology Core, National Cancer Center Research Institute, Tokyo, Japan

  ⨯
• Hironobu Minami,

  Affiliation Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Tatsuya Ioka

  Affiliation Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

  ⨯